Azenta Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $613.8M+7.0% YoYTTM through 30 Jun 2026
Net Income -$122.9MTTM through 30 Jun 2026
Free Cash Flow $9.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 45.5% |
| EBITDA Margin | -19.5% |
| Operating Margin | -4.5% |
| Net Margin | -20.0% |
Returns
-3.5%ROE
-2.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.50x
Net Debt-$340.9Mnet cash position
Cash & Equivalents$189.7M
Quality Metrics
Altman Z-Score3.67
Piotroski F-Score5 / 9
FCF Margin1.6%
Rule of 401.8
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $593.8M
Diluted EPS-$2.67TTMFY2025: $-1.22
Dividend
$0.40Per share, FY20210.00%Yield+14.9%5-yr growth
Capital Allocation
R&D Spend$35.7M
Capex Intensity4.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sample Management Solutions | $325M | +1.9% | |
| Multiomics | $269M | +5.5% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.